Loading
Dengue Vaccines / Antibodies, Monoclonal / Host-directed Therapy · Journal article
Emerging Microbes & Infections · June 21, 2026
A consensus or society position rather than new primary data.
This is a narrative literature review synthesizing current knowledge on dengue virus biology, therapeutic approaches (vaccines, antivirals, monoclonal antibodies), and preventive strategies. It contextualizes recent advances in development stage and mechanistic insight without conducting systematic meta-analysis or reporting original trial data. The review emphasizes that despite decades of research, no universally protective vaccine or widely approved antiviral therapy exists, and highlights the challenge of antibody-dependent enhancement across multiple intervention classes.
Narrative (non-systematic) review. Global populations in tropical and subtropical regions, with emerging threat in Europe; emphasis on regions with limited disease diagnosis and surveillance capacities; dengue virus four serotypes (DENV-1 to DENV-4) circulating in Aedes aegypti and Aedes albopictus mosquito-endemic areas..
Global reported dengue case numbers reached over 6.5 million in 2023, with 1900 deaths reported in 2025 to date Four antigenically distinct dengue virus serotypes share approximately 65% genomic homology and elicit partially distinct but cross-reactive immune responses Live-attenuated and chimeric tetravalent vaccines have progressed from early development to advanced clinical trials, demonstrating promising immunogenicity, safety, and potential for simplified dosing regimens
No specific efficacy, safety, or comparative effectiveness data reported for individual vaccines, antivirals, or monoclonal antibodies Live-attenuated and chimeric tetravalent vaccines have progressed from early development to advanced clinical trials, demonstrating promising immunogenicity, safety, and potential for simplified dosing regimens
Clinicians and researchers should recognize that this review provides an integrated landscape of dengue prevention and treatment modalities currently in development, highlighting that no universal solution yet exists. The emphasis on antibody-dependent enhancement risk and serotype diversity underscores the need for careful appraisal of emerging vaccines, antivirals, and monoclonal antibodies before clinical deployment.
A narrative review synthesizing current knowledge on dengue therapeutics (vaccines, antivirals, monoclonal antibodies) without original data or systematic analysis, offering translational context on development stage and mechanistic insight for clinical and research audiences.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians and researchers should recognize that this review provides an integrated landscape of dengue prevention and treatment modalities currently in development, highlighting that no universal solution yet exists. The emphasis on antibody-dependent enhancement risk and serotype diversity underscores the need for careful appraisal of emerging vaccines, antivirals, and monoclonal antibodies before clinical deployment.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Dengue virus (DENV) continues to pose a major global health challenge, with widespread distribution, frequent outbreaks, and four antigenically distinct serotypes complicating efforts for effective prevention and treatment. Despite decades of research, no universally protective vaccine or widely approved therapeutic exists, and the risk of antibody-dependent enhancement further complicates intervention strategies. This review provides an integrated perspective on dengue prevention and treatment, positioning vaccines, monoclonal antibodies, antiviral drugs, and host-directed therapies along the continuum of infection. It synthesizes recent advances in dengue prophylaxis and therapy, highlighting key innovations in vaccines, monoclonal antibodies, and antiviral compounds. Live-attenuated and chimeric tetravalent vaccines have progressed from early development to advanced clinical trials, demonstrating promising immunogenicity, safety, and potential for simplified dosing regimens. Concurrently, engineered monoclonal antibodies targeting conserved viral epitopes have improved neutralization breadth and reduced enhancement risk, while combination strategies may further limit viral escape. Antiviral development has explored both direct-acting and host-directed mechanisms, revealing potent candidates in preclinical models, although clinical translation remains challenging. Together, these advances illustrate a multifaceted approach to dengue control, integrating vaccine optimization, rational antibody design, and targeted therapeutics. By contextualizing recent progress and remaining challenges, this review underscores the urgent need for coordinated efforts to develop safe, effective, and broadly deployable interventions, ultimately supporting global efforts to reduce the burden of dengue.Trial registration: ClinicalTrials.gov identifier: NCT04722627, NCT05201794, NCT06006559, NCT05710224, NCT04273217.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.